Neurocognitive Impairment
7
0
0
5
Key Insights
Highlights
Success Rate
83% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 59/100
14.3%
1 terminated out of 7 trials
83.3%
-3.2% vs benchmark
0%
0 trials in Phase 3/4
40%
2 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (7)
eHealth Insomnia Intervention for Adult Survivors of Childhood Cancer
Effects of Docosahexanoic Acid on Neurocognitive Impairment in HIV-infected Patients
Effects of Diet on Brain Processing
Brain Imaging for HIV-Associated Thinking and Mood Disorders
Neurocognitive Functioning in Patients With Newly Diagnosed Upper Aerodigestive Tract Cancer Receiving Treatment at Henry-Joyce Cancer Clinic
Risk of Psychopathology and Neurocognitive Impairment in Leukemia Survivors
Examining a Common Complaint of Women Who Receive Chemotherapy for Breast Cancer- Cognitive Difficulty